Suchergebnisse - "Prawira, Amy"

PubPharm (26)

1

Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors : A first-in-human, dose-escalation, and dose-expansion study

enthalten in: Cancer | 2024

von Bishnoi, S. | Kotasek, D. | Aghmesheh, M. | +14

2

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

enthalten in: British journal of cancer | 2023

von Day, D. | Park, J. | Coward, J. | +16

3

Selinexor for the treatment of recurrent or metastatic salivary gland tumors : Results from the GEMS-001 clinical trial

enthalten in: Cancer medicine | 2023

von Hernando-Calvo, A. | Malone, E. | Day, D. | +11

4

Impact of travel distance on outcomes for clinical trial patients : the Kinghorn Cancer Centre experience

enthalten in: Internal medicine journal | 2023

von Lim, J. | Akbar Ali, S. | Prawira, A. | +1

CommentOn: BMJ Open. 2016 Nov 24;6(11):e013059. - PMID 27884848

5

Impact of travel distance on outcomes for clinical trial patients : the Kinghorn Cancer Centre experience

enthalten in: Internal Medicine Journal | 2023

von Lim, J. | Akbar Ali, S. | Prawira, A. | +1

6

Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial.

enthalten in: ResearchSquare.com | 2022

von Hernando-Calvo, A. | Malone, E. | Day, D. | +10

7

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors : interim results from a multicenter phase I/II trial

enthalten in: Journal for immunotherapy of cancer | 2022

von Aggarwal, C. | Prawira, A. | Antonia, S. | +26

8

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

enthalten in: Journal for immunotherapy of cancer | 2022

von Schöffski, P. | Tan, D. | Martín, M. | +29

9

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

enthalten in: Journal for ImmunoTherapy of Cancer | February 25, 2022

von Schöffski, P. | Tan, D. | Martín, M. | +29

10

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer : SNOW window-of-opportunity study

enthalten in: Journal for immunotherapy of cancer | 2021

von Oliva, M. | Chepeha, D. | Araujo, D. | +29